Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome

#1354

Introduction: Telotristat etiprate (TE) reduces serotonin production. In TELESTAR, a phase 3 study in patients (pts) with carcinoid syndrome (CS) on somatostatin analogues with ≥4 bowel movements (BM) per day, TE significantly reduced BM frequency (freq). Overall (n=135), durable response (DR, ≥30% reduction in BMs/day for ≥50% of the study period) was observed in 44% (250 mg tid) and 42% (500 mg tid), vs 20% on placebo (PBO); p≤0.02 for each TE vs. PBO. A subset with similar demographics to the overall trial was interviewed.

Aim(s): To assess pt reported impact of treatment (tx) on CS and whether symptom changes were meaningful.

Materials and methods: Participating sites were asked to invite (prior to randomization) all eligible pts to phone interviews scheduled at the end of the double-blind tx period. Pts and interviewers were blinded to tx.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Pavel M, Hörsch D, Anthony L, Ervin C, Kulke M,

Keywords: serotonin, bowel movement, durable response, treatment satisfaction,